Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 63
Filtrar
1.
Int. j. cardiovasc. sci. (Impr.) ; 32(5): 508-516, Sept-Oct. 2019. tab, graf
Artigo em Inglês | LILACS-Express | ID: biblio-1040105

RESUMO

Abstract Background: The study is based on the fact that left atrial (LA) volume measurement is a marker of the presence of diastolic dysfunction and that Vitamin D deficiency may be associated with ventricular remodeling, worsening of left ventricular (LV) diastolic and systolic function, and activation of the renin-angiotensin-aldosterone system. Objective: To evaluate whether LAV changes are related to vitamin D deficiency. Method: A cross-sectional, population-based, unicentric study in which 640 patients over 45 years of age enrolled in the Niterói's Médico de Família program, RJ, were evaluated. Patients were submitted to tissue Doppler echocardiography to evaluate the parameters of diastolic and systolic function and vitamin D dosage. The presence or absence of hypovitaminosis D associated with structural and functional cardiac changes was compared between each group. A p < 0.05 value was considered as an indicator of statistical significance. Results: Of the 640 individuals analyzed, hypovitaminosis D was confirmed in 39.2% of the patients, of whom 34.8% had diastolic dysfunction. The most relevant echocardiographic parameters that were statistically significant were non-indexed AEDs and LAV, E'/A' and E wave deceleration time, which were associated with the presence of hypovitaminosis D (P < 0.01). Conclusion: The study of the association of hypovitaminosis D and the appearance of structural and functional cardiac abnormalities may contribute to the discussion of the adoption of one more criterion to select individuals at risk of developing clinical cardiac insufficiency in primary care since, with the use of echocardiography, the subclinical condition of cardiac involvement, with prognostic and treatment implications for the referred patients with hypovitaminosis D, can be identified early.

7.
Int. j. cardiovasc. sci. (Impr.) ; 31(6): 643-651, nov.- dez. 2018. ilus, graf
Artigo em Inglês | LILACS | ID: biblio-979982

RESUMO

Sepsis remains the leading cause of mortality and critical illness worldwide. Myocardial dysfunction is one of the most clinically relevant manifestations of sepsis and results from a complex interaction among genetic, molecular, metabolic, and structural changes. Despite the prominence given to the occurrence of systolic dysfunction during sepsis, the association between diastolic dysfunction and mortality is controversial, while diastolic dysfunction and right ventricular dysfunction are identified as independent predictors of mortality in the most recent studies. Elevation of biomarkers during sepsis may result from several mechanisms, and although the role of the B-type natriuretic peptide (BNP) and the N-terminal portion of its prohormone (NT-proBNP) as independent predictors of mortality is well defined, the same cannot be said about cardiac troponins due to conflicting results among currently available studies. The objective of the present review is to discuss the pathophysiological mechanisms of myocardial dysfunction induced by sepsis in adults and the role of echocardiography and cardiac biomarkers as tools for prognostic evaluation in this clinical setting


Assuntos
Humanos , Masculino , Feminino , Adulto , Ecocardiografia/métodos , Biomarcadores , Sepse/mortalidade , Prognóstico , Canais de Cálcio , Doenças Cardiovasculares/fisiopatologia , Fatores de Risco , Disfunção Ventricular Direita/mortalidade , Disfunção Ventricular Esquerda/mortalidade , Adulto
8.
Arq Bras Cardiol ; 111(2): 205-212, 2018 Aug.
Artigo em Inglês, Português | MEDLINE | ID: mdl-30183988

RESUMO

Breast cancer is the most frequently diagnosed tumor in women worldwide, with a significant impact on morbidity and mortality. Chemotherapy and hormone therapy have significantly reduced mortality; however, the adverse effects are significant. Aspirin has been incorporated into clinical practice for over 100 years at a low cost, making it particularly attractive as a potential agent in breast cancer prevention and as an adjunct treatment to endocrine therapy in the prophylaxis of cardiovascular complications. The objective of this study was to evaluate the role of aspirin in reducing the incidence of breast cancer and to evaluate the impact of its use on morbidity and mortality and reduction of cardiovascular events as adjuvant therapy during breast cancer treatment with selective estrogen receptor modulators. A systematic review was performed using the PRISMA methodology and PICO criteria, based on the MEDLINE, EMBASE and LILACS databases. The original articles of clinical trials, cohort, case-control studies and meta-analyses published from January 1998 to June 2017, were considered. Most studies showed an association between the use of selective estrogen receptor modulators and the increase in thromboembolic events. The studies suggest a protective effect of aspirin for cardiovascular events during its concomitant use with selective estrogen receptor modulators and in the prevention of breast cancer. This systematic review suggests that aspirin therapy combines the benefit of protection against cardiovascular events with the potential reduction in breast cancer risk, and that the evaluation of the benefits of the interaction of endocrine therapy with aspirin should be further investigated.


Assuntos
Antineoplásicos Hormonais/administração & dosagem , Aspirina/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Inibidores da Agregação de Plaquetas/administração & dosagem , Medicina Baseada em Evidências , Feminino , Humanos
9.
Arq. bras. cardiol ; 111(2): 205-212, Aug. 2018. tab, graf
Artigo em Inglês | LILACS-Express | ID: biblio-950222

RESUMO

Abstract Breast cancer is the most frequently diagnosed tumor in women worldwide, with a significant impact on morbidity and mortality. Chemotherapy and hormone therapy have significantly reduced mortality; however, the adverse effects are significant. Aspirin has been incorporated into clinical practice for over 100 years at a low cost, making it particularly attractive as a potential agent in breast cancer prevention and as an adjunct treatment to endocrine therapy in the prophylaxis of cardiovascular complications. The objective of this study was to evaluate the role of aspirin in reducing the incidence of breast cancer and to evaluate the impact of its use on morbidity and mortality and reduction of cardiovascular events as adjuvant therapy during breast cancer treatment with selective estrogen receptor modulators. A systematic review was performed using the PRISMA methodology and PICO criteria, based on the MEDLINE, EMBASE and LILACS databases. The original articles of clinical trials, cohort, case-control studies and meta-analyses published from January 1998 to June 2017, were considered. Most studies showed an association between the use of selective estrogen receptor modulators and the increase in thromboembolic events. The studies suggest a protective effect of aspirin for cardiovascular events during its concomitant use with selective estrogen receptor modulators and in the prevention of breast cancer. This systematic review suggests that aspirin therapy combines the benefit of protection against cardiovascular events with the potential reduction in breast cancer risk, and that the evaluation of the benefits of the interaction of endocrine therapy with aspirin should be further investigated.


Resumo O câncer de mama é o tumor mais frequentemente diagnosticado em mulheres de todo o mundo, com impacto importante na morbimortalidade. A quimioterapia e a terapia hormonal reduziram significativamente a mortalidade, mas os efeitos adversos são consideráveis. A aspirina está incorporada à prática clínica há mais de 100 anos, com baixo custo, tornando-a particularmente atraente como potencial agente na prevenção do câncer de mama e auxiliar durante o tratamento endócrino, na profilaxia de complicações cardiovasculares. Objetivou-se avaliar o papel da aspirina na redução da incidência do câncer de mama e avaliar o impacto de seu uso na morbimortalidade e na redução de eventos cardiovasculares como terapia adjuvante durante o tratamento do câncer de mama com moduladores seletivos do receptor do estrogênio. Procedeu-se à revisão sistemática utilizando-se a metodologia PRISMA e os critérios PICO, nas bases MEDLINE, EMBASE e LILACS. Foram considerados os artigos originais do tipo ensaio clínico, coorte, caso-controle e metanálises, publicados no período de janeiro de 1998 até junho de 2017. Na maioria dos estudos, houve relação entre o uso dos moduladores seletivos do receptor do estrogênio e o aumento de eventos tromboembólicos. Os estudos sugerem efeito protetor da aspirina para eventos cardiovasculares em uso concomitante aos moduladores seletivos do receptor do estrogênio e na prevenção do câncer de mama. Esta revisão sistemática sugere que o tratamento com aspirina combina o benefício da proteção contra eventos cardiovasculares com a potencial redução do risco de câncer de mama, e que a avaliação dos benefícios da interação da terapia endócrina com a aspirina deve ser melhor investigada.

11.
Int. j. cardiovasc. sci. (Impr.) ; 31(4): 422-432, jul.-ago. 2018. tab, ilus
Artigo em Inglês | LILACS | ID: biblio-954121

RESUMO

Vitamin D is considered a steroid hormone with a broad spectrum of action in the human body. Its action arises from the binding of its active metabolite (1α,25-dihydroxyvitamin D) to its receptor (VDR), which is present throughout the body, including vascular smooth muscle cells and cardiomyocytes. Initially, vitamin D deficiency was related only to changes in the musculoskeletal system, but in recent years, researchers have demonstrated its relationship with several pathologies related to other systems, such as cardiovascular diseases. The objective of this study is to review vitamin D's pathophysiology, describe its relationship with cardiovascular diseases based on the most recent publications, and highlight the results of vitamin supplementation in the prevention of such pathologies


A vitamina D é considerada um hormônio esteroide com amplo espectro de atuação no organismo humano. Sua ação ocorre a partir da ligação do seu metabólito ativo (1α,25-di-hidroxivitamina D) com seu receptor (VDR) que se encontra presente em todo o organismo, inclusive nas células musculares lisas vasculares e nos cardiomiócitos. Inicialmente, a deficiência de vitamina D havia sido relacionada apenas com alterações no sistema musculoesquelético. Porém, nos últimos anos, pesquisadores têm demonstrado sua relação com diversas patologias pertencentes a outros sistemas, tais como as doenças cardiovasculares. O objetivo deste trabalho foi revisar a fisiopatologia da vitamina D, descrever sua relação com as doenças cardiovasculares com base nas publicações mais recentes e destacar os resultados da suplementação vitamínica na prevenção de tais patologias


Assuntos
Humanos , Masculino , Feminino , Vitamina D , Deficiência de Vitamina D/fisiopatologia , Doenças Cardiovasculares/prevenção & controle , Deficiência de Vitaminas , Tabagismo , Índice de Massa Corporal , Ergocalciferóis/deficiência , Prevalência , Análise Multivariada , Fatores de Risco , Colecalciferol/deficiência , Diabetes Mellitus , Insuficiência Cardíaca , Hipertensão , Obesidade
12.
Int. j. cardiovasc. sci. (Impr.) ; 31(4)jul.-ago. 2018. ilus, tab
Artigo em Português | LILACS | ID: biblio-910647

RESUMO

A vitamina D é considerada um hormônio esteroide com amplo espectro de atuação no organismo humano. Sua ação ocorre a partir da ligação do seu metabólito ativo (1α, 25-di-hidroxivitamina D) com seu receptor (VDR) que se encontra presente em todo o organismo, inclusive nas células musculares lisas vasculares e nos cardiomiócitos. Inicialmente, a deficiência de vitamina D havia sido relacionada apenas com alterações no sistema musculoesquelético. Porém, nos últimos anos, pesquisadores têm demonstrado sua relação com diversas patologias pertencentes a outros sistemas, tais como as doenças cardiovasculares. O objetivo deste trabalho foi revisar a fisiopatologia da vitamina D, descrever sua relação com as doenças cardiovasculares com base nas publicações mais recentes e destacar os resultados da suplementação vitamínica na prevenção de tais patologias


Assuntos
Humanos , Masculino , Feminino , Doenças Cardiovasculares/prevenção & controle , Vitamina D , Deficiência de Vitamina D/fisiopatologia , Deficiência de Vitaminas , Índice de Massa Corporal , Colecalciferol , Diabetes Mellitus , Suplementos Nutricionais , Ergocalciferóis , Insuficiência Cardíaca , Hipertensão , Análise Multivariada , Obesidade Mórbida , Prevalência , Fatores de Risco , Tabagismo
14.
Rev Port Cardiol ; 37(6): 539.e1-539.e2, 2018 06.
Artigo em Inglês, Português | MEDLINE | ID: mdl-29753564

RESUMO

Patients with thoracic aortic aneurysm (TAA) are mostly asymptomatic and TAA is rarely related to heart failure (HF). We report the case of an 80-year-old female patient, with type A TAA without dissection, with right pulmonary artery and left atrium compression, who presented with HF, preserved ejection fraction and acute pulmonary edema.

16.
J Bras Nefrol ; 39(3): 246-252, 2017 Jul-Sep.
Artigo em Inglês, Português | MEDLINE | ID: mdl-28902230

RESUMO

INTRODUCTION: Cardiovascular disease (CVD) is especially prevalent in patients with chronic kidney disease (CKD). OBJECTIVE: To evaluate the role of CKD and metabolic syndrome (MS), which is a cluster of risk factors for CVD, as predictors of CVD. METHODS: Observational, cross-sectional study with a random sample aged 45 or more years extracted from the population assisted by the primary care program in Niterói city in the state of Rio de Janeiro, Brazil. CKD was diagnosed by the K/DOQI guidelines and MS, by the harmonized criteria. CVD was said to be present if the participant had one or more of the following findings: echocardiographic abnormalities, and history of myocardial infarction, stroke or heart failure. A logistic regression model was developed to analyze risk factors for CVD using CKD as the variable of primary interest. RESULTS: Fifty hundred and eighty-one participants (38.2% male) with a mean age of 59.4 ± 10.2 years were analyzed. The prevalence rate of CKD was 27.9%. In participants without CKD, MS was associated with a slight but statistically significant increase in the risk for CVD (OR = 1.52, p = 0.037); in those with CKD but without MS the risk for CVD was also statistically significant and at a greater magnitude (OR = 2.42, p = 0.003); when both were present the risk for CVD was substantially higher (OR = 5.13, p < 0.001). CONCLUSION: In this study involving a population assisted by a primary care program, CKD was confirmed as an independent risk factor for CVD. The presence of MS concurrent with CKD substantially amplified the risk for CVD.


Assuntos
Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Síndrome Metabólica/complicações , Insuficiência Renal Crônica/complicações , Idoso , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Atenção Primária à Saúde , Fatores de Risco
18.
J. bras. nefrol ; 39(3): 246-252, July-Sept. 2017. tab
Artigo em Inglês | LILACS-Express | ID: biblio-893770

RESUMO

Abstract Introduction: Cardiovascular disease (CVD) is especially prevalent in patients with chronic kidney disease (CKD). Objective: To evaluate the role of CKD and metabolic syndrome (MS), which is a cluster of risk factors for CVD, as predictors of CVD. Methods: Observational, cross-sectional study with a random sample aged 45 or more years extracted from the population assisted by the primary care program in Niterói city in the state of Rio de Janeiro, Brazil. CKD was diagnosed by the K/DOQI guidelines and MS, by the harmonized criteria. CVD was said to be present if the participant had one or more of the following findings: echocardiographic abnormalities, and history of myocardial infarction, stroke or heart failure. A logistic regression model was developed to analyze risk factors for CVD using CKD as the variable of primary interest. Results: Fifty hundred and eighty-one participants (38.2% male) with a mean age of 59.4 ± 10.2 years were analyzed. The prevalence rate of CKD was 27.9%. In participants without CKD, MS was associated with a slight but statistically significant increase in the risk for CVD (OR = 1.52, p = 0.037); in those with CKD but without MS the risk for CVD was also statistically significant and at a greater magnitude (OR = 2.42, p = 0.003); when both were present the risk for CVD was substantially higher (OR = 5.13, p < 0.001). Conclusion: In this study involving a population assisted by a primary care program, CKD was confirmed as an independent risk factor for CVD. The presence of MS concurrent with CKD substantially amplified the risk for CVD.


Resumo Introdução: A doença cardiovascular (DCV) é especialmente prevalente em pacientes com doença renal crônica (DRC). Objetivo: Avaliar o papel da DRC e da síndrome metabólica (SM), que é um conjunto de fatores de risco para DCV, como previsores de DCV. Métodos: Estudo observacional, transversal, com uma amostra representativa da população assistida pelo programa de atenção primária em Niterói, RJ, Brasil, incluindo pacientes com idade igual ou maior do que 45 anos. A DRC foi diagnosticada segundo o K/DOQI e a SM, pelo critério harmonizado. A DCV foi dita estar presente diante de um ou mais dos seguintes achados: anormalidades ecocardiográficas ou história de infarto do miocárdio, acidente vascular cerebral ou insuficiência cardíaca. Um modelo de regressão logística foi desenvolvido para analisar os fatores de risco cardiovasculares usando a DRC como a variável de interesse primário. Resultados: Foram analisados 581 participantes (38,2% homens), com idade média de 59,4 ± 10,2 anos. A taxa de prevalência da DRC foi de 27,9%. Em participantes sem DRC, a SM foi associada com um ligeiro, mas estatisticamente significativo aumento no risco cardiovascular (OR = 1,52, p = 0,04); naqueles com DRC, mas sem SM, o risco para DCV também foi estatisticamente significativo e com maior magnitude (OR = 2,42, p = 0,003); quando ambos estavam presentes, o risco para DCV foi substancialmente mais elevado (OR = 5,13, p < 0,001). Conclusão: Neste estudo, envolvendo uma população assistida por um programa de atenção primária, a DRC foi confirmada como um fator de risco independente para DCV. A presença da SM concomitante com a DRC ampliou substancialmente esse risco.

19.
Arq. bras. cardiol ; 109(3): 248-252, Sept. 2017. tab
Artigo em Inglês | LILACS-Express | ID: biblio-887926

RESUMO

Abstract Background: Heart failure (HF) is a major public health issue with implications on health-related quality of life (HRQL). Objective: To compare HRQL, estimated by the Short-Form Health Survey (SF-36), in patients with and without HF in the community. Methods: Cross-sectional study including 633 consecutive individuals aged 45 years or older, registered in primary care. The subjects were selected from a random sample representative of the population studied. They were divided into two groups: group I, HF patients (n = 59); and group II, patients without HF (n = 574). The HF group was divided into HF with preserved ejection fraction (HFpEF - n = 35) and HF with reduced ejection fraction (HFrEF - n = 24). Results: Patients without HF had a mean SF-36 score significantly greater than those with HF (499.8 ± 139.1 vs 445.4 ± 123.8; p = 0.008). Functional capacity - ability and difficulty to perform common activities of everyday life - was significantly worse (p < 0.0001) in patients with HF independently of sex and age. There was no difference between HFpEF and HFrEF. Conclusion: Patients with HF had low quality of life regardless of the syndrome presentation (HFpEF or HFrEF phenotype). Quality of life evaluation in primary care could help identify patients who would benefit from a proactive care program with more emphasis on multidisciplinary and social support. (Arq Bras Cardiol. 2017; [online].ahead print, PP.0-0)


Resumo Fundamento: A insuficiência cardíaca (IC) é um importante problema de saúde pública, com implicações na qualidade de vida relacionada à saúde (QVRS). Objetivo: Comparar a QVRS, estimada através do Questionário SF-36 (Short-Form Health Survey), em pacientes com e sem IC na comunidade. Métodos: Estudo transversal incluindo 633 indivíduos consecutivos com idade igual ou superior a 45 anos, registrados na atenção primária e selecionados de uma amostra aleatória representativa da população estudada. Foram divididos em dois grupos: grupo I, pacientes com IC (n = 59); e grupo II, pacientes sem IC (n = 574). O grupo I foi dividido em pacientes com IC com fração de ejeção preservada (ICFEP - n = 35) e pacientes com IC com fração de ejeção reduzida (ICFER - n = 24). Resultados: Pacientes sem IC tiveram um escore médio do SF-36 significativamente maior do que aqueles com IC (499,8 ± 139,1 vs 445,4 ± 123,8; p = 0,008). A capacidade funcional - habilidade e dificuldade para realizar atividades comuns da vida diária - foi significativamente pior (p < 0,0001) nos pacientes com IC independentemente de sexo e idade. Não houve diferença entre ICFEP e ICFER. Conclusão: Pacientes com IC mostraram baixa qualidade de vida a despeito da apresentação da síndrome (fenótipo ICFEP ou ICFER). A avaliação da qualidade de vida na atenção primária poderia auxiliar a identificar pacientes que se beneficiariam de um programa de atenção à saúde pró-ativo com maior ênfase em suporte multidisciplinar e social. (Arq Bras Cardiol. 2017; [online].ahead print, PP.0-0)

20.
Arq Bras Cardiol ; 109(3): 248-252, 2017 Sep.
Artigo em Inglês, Português | MEDLINE | ID: mdl-28832746

RESUMO

BACKGROUND: Heart failure (HF) is a major public health issue with implications on health-related quality of life (HRQL). OBJECTIVE: To compare HRQL, estimated by the Short-Form Health Survey (SF-36), in patients with and without HF in the community. METHODS: Cross-sectional study including 633 consecutive individuals aged 45 years or older, registered in primary care. The subjects were selected from a random sample representative of the population studied. They were divided into two groups: group I, HF patients (n = 59); and group II, patients without HF (n = 574). The HF group was divided into HF with preserved ejection fraction (HFpEF - n = 35) and HF with reduced ejection fraction (HFrEF - n = 24). RESULTS: Patients without HF had a mean SF-36 score significantly greater than those with HF (499.8 ± 139.1 vs 445.4 ± 123.8; p = 0.008). Functional capacity - ability and difficulty to perform common activities of everyday life - was significantly worse (p < 0.0001) in patients with HF independently of sex and age. There was no difference between HFpEF and HFrEF. CONCLUSION: Patients with HF had low quality of life regardless of the syndrome presentation (HFpEF or HFrEF phenotype). Quality of life evaluation in primary care could help identify patients who would benefit from a proactive care program with more emphasis on multidisciplinary and social support. (Arq Bras Cardiol. 2017; [online].ahead print, PP.0-0).


Assuntos
Insuficiência Cardíaca/psicologia , Atenção Primária à Saúde , Qualidade de Vida/psicologia , Idoso , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA